
|Articles|September 1, 2002
Dual 5-alpha-reductase inhibitor reduces BPH symptoms
Orlando, FL-A newer, novel 5-alpha-reductase inhibitor offersBPH symptom relief and improvements in urinary flow rates, according tofindings from three 2-year, multicenter, phase III trials.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5








